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ABSTRACT
Between 1 January 2003 and 31 December 2003, 37 patients had positive cultures of pandrug-resistant
Pseudomonas aeruginosa (PDRPA) resistant to all commercially available anti-pseudomonal antimicrobial
agents in Taiwan, including anti-pseudomonal penicillins, ceftazidime, fourth-generation cephalospo-
rins, aztreonam, carbapenems, aminoglycosides and ciproﬂoxacin. Nineteen (51.4%) patients had
PDRPA infections, including pneumonia (17 patients), catheter-related bacteraemia (one patient) and
anal abscess (one patient). Eighteen patients were classiﬁed as having PDRPA colonisation, based on
absence of clinical signs or symptoms of infection. In total, 92 isolates were recovered from various
specimens, with the majority (85.9%) recovered from respiratory tract secretions (sputa, bronchial
washings and pleural effusions), followed by urine (4.3%) and catheter tips (3.3%). Twenty-eight
(75.7%) patients yielded cultures of non-PDR P. aeruginosa isolates before isolation of PDRPA, with a
mean period between the ﬁrst isolation of non-PDR P. aeruginosa and the isolation of PDRPA of
128.3 days. Most patients had received b-lactam antibiotics, ﬂuoroquinolones or carbapenems for
prolonged periods. Univariate analysis showed that PDRPA infection, male gender and the presence of
fever at the time of PDRPA isolation were associated with increased mortality.
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INTRODUCTION
Pseudomonas aeruginosa is one of the main organ-
isms responsible for drug-resistant nosocomial
infections, and is one of the leading causes
of bacteraemia and pneumonia in hospitalised
patients [1,2]. In addition to being intrinsically
resistant to several antimicrobial agents, P. aeru-
ginosa acquires resistance readily to conventional
anti-pseudomonal antibiotics (i.e., anti-pseudo-
monal penicillins, ceftazidime, fourth-generation
cephalosporins, aztreonam, carbapenems and
ciproﬂoxacin) following prolonged use of these
antibiotics in hospitalised patients, particularly
patients in intensive care units (ICUs) [3–10].
Multidrug-resistant (resistant to at least three
different classes of antibiotics) P. aeruginosa
(MDRPA) strains were ﬁrst reported in patients
with cystic ﬁbrosis [11], and dissemination of
these resistant organisms has since been reported
among hospitalised patients [12–15]. P. aeruginosa
isolates resistant to carbapenems, or resistant to all
antibiotics available for clinical use (PDRPA), have
been reported to cause nosocomial infections and
outbreaks among patients hospitalised in ICUs or
burn units [16,17].
At National Taiwan University Hospital
(NTUH), the ﬁrst isolate of PDRPA (formerly
MDRPA) was recovered from the wound of a
burn patient in December 1996 [17]. Since then,
PDRPA isolates have spread widely in NTUH
[17,18]. A previous study of 26 PDRPA isolates
revealed that 73% of these isolates possessed the
blaVIM-3 gene, and that 96% harboured class I
integrons [18]. Molecular investigations demon-
strated the polyclonal nature of these isolates,
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although clonal dissemination of PDRPA isolates
among patients had also occurred [18]. The
present study describes the epidemiology, clinical
features and outcomes of hospitalised patients
colonised or infected with PDRPA, and assesses
the risk-factors for acquisition of these pan-resist-
ant organisms.
MATERIALS AND METHODS
Setting
NTUH is a tertiary medical centre located in northern Taiwan.
The hospital has 2000 beds, including 150 beds in the ICU.
During 2003, 54 574 patients were admitted to the hospital,
including 3953 patients admitted to the ICU.
Bacterial isolates and susceptibility testing
Microbiology records between 1 January 2003 and 31 Decem-
ber 2003 from the NTUH Clinical Bacteriology Laboratory
were analysed to identify patients harbouring PDRPA isolates.
A PDRPA isolate was deﬁned as being resistant to all
commercially available anti-pseudomonal antibiotics in
Taiwan (i.e., ceftazidime, cefepime, ticarcillin ⁄ clavulanate,
piperacillin ⁄ tazobactam, aztreonam, imipenem, meropenem,
gentamicin, amikacin, levoﬂoxacin and ciproﬂoxacin). Stand-
ard disk susceptibility tests were performed and interpreted as
recommended by NCCLS guidelines [19]. Susceptibility of
PDRPA isolates to colistin was also determined using the
standard disk-diffusion method [18]. Ticarcillin, piperacillin,
cefoperazone, cefoperazone-sulbactam and colistin are not
available for clinical use in Taiwan.
Patients
The medical records of all patients with a PDRPA isolate were
reviewed retrospectively. Clinical data collected included
demographic characteristics, co-morbid diseases, clinical diag-
noses, length of hospital stay, classes and duration of antibiotic
use before notiﬁcation of positive culture results for PDRPA.
Data on clinical parameters included signs of sepsis, shock, use
of an indwelling catheter, invasive diagnostic and therapeutic
procedures, and laboratory examinations. The severity of each
patient’s clinical condition was evaluated using the multiple
organ dysfunction score (MODS) [20]. Patients were classiﬁed
as immunosuppressed if they had received steroids, chemo-
therapy for malignancy or immunomodulatory agents (for
autoimmune disease or transplantation), or if they had
diabetes mellitus, infection with human immunodeﬁciency
virus (HIV), or a malignancy known to suppress autoimmune
function (such as lymphoma). Classiﬁcation of patients as
infected or colonised was according to the criteria of the CDC
National Nosocomial Infections Surveillance System (NNIS)
[21]. Colonisation was deﬁned as the isolation of a pathogen
from any site without signs or symptoms of infection.
Pneumonia was diagnosed based on the ﬁnding of a new or
progressive inﬁltration following chest radiography in a
patient meeting at least two of the following criteria: fever
>38.3C or hypothermia <36C; leukopenia or leukocytosis;
and purulent tracheal secretion. PDRPA recovered from
respiratory secretions (sputum or bronchial washes) was
considered to be the aetiological agent of pneumonia if Gram’s
stain revealed >25 polymorphonuclear neutrophils (PMNs)
and <10 epithelial cells ⁄ low power ﬁeld, a predominance of
Gram-negative slender bacilli intracellularly or surrounding
the PMNs, and if PDRPA was the predominant or pure isolate
on blood agar plates. If these criteria were not met, PDRPA
was considered to be a coloniser of the respiratory tract.
Statistical analysis
Proportions were compared using chi-square or univariate
analysis to determine the factors inﬂuencing prognosis. Dif-
ferences were considered signiﬁcant if p was < 0.05. A
multivariate analysis on the variables by the backward method
was also performed for factors with p < 0.1 in the univariate
analysis. Analyses were performed using SPSS v.10.0 software
(SPSS Inc., Chicago, IL, USA).
RESULTS
In total, 37 patients yielded a positive culture of
PDRPA from various clinical specimens during
the study period. The demographic and clinical
characteristics of these patients are summarised in
Table 1. Ninety-two isolates of PDRPA were
obtained from 75 (81.5%) sputa, four (4.3%)
urines, three (3.3%) catheter tips, three (3.3%)
surgical wounds, three (3.3%) bronchial washes,
two (2.2%) anal swab or stool cultures, one (1.1%)
pleural effusion, and one (1.1%) blood culture.
Grouped according to the source of the ﬁrst
isolate of PDRPA, the organisms were obtained
from 29 (78.4%) sputa, three (8.1%) urines, two
(5.4%) catheter tips, one (2.7%) surgical wound,
one (2.7%) anal swab or stool culture, and one
(2.7%) pleural effusion.
Data concerning treatment with speciﬁc antibi-
otics before acquisition of PDRPA are shown in
Table 2. The antibiotic used most frequently was
ciproﬂoxacin (20 patients; 54.1%), followed by
imipenem (18 patients; 48.6%) and cefepime or
ceftazidime (15 patients; 45%). The antibiotics
with the longest mean duration of usage were
ciproﬂoxacin (34.4 days), imipenem (29.1 days)
and amikacin (25.6 days). All PDRPA isolates
were susceptible to colistin, with inhibition zone
diameters around the colistin disks of 12–14 mm.
Signiﬁcant factors predicting in-hospital mor-
tality after positive PDRPA culture were gender,
infection or colonisation, and fever (Table 3). Age,
diabetes mellitus, cancer, heart disease, haemodi-
alysis, renal disease, leukocytosis, shock, dissem-
inated intravascular coagulation, MODS >6 and
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mechanical ventilation were not signiﬁcant pre-
dictors of hospital death. Fig. 1 compares the
survival probability of patients with PDRPA
infection and patients with PDRPA colonisation.
Multivariate analysis (Table 4) showed that fever
was the only signiﬁcant factor predicting in-hos-
pital mortality after removing the gender factor in
the backward method. Fever tended to be seen
more frequently in males than in females (52% vs.
21%; p 0.090).
DISCUSSION
Signiﬁcant predictors of in-hospital mortality after
positive PDRPA culture were gender, infection or
colonisation, and fever. The greater number of
male patients with PDRPA infection may be
related to the relatively smaller body size of
female patients. In this study, most patients with
PDRPA infection were male (15 ⁄ 19; 78.4%) and
had fever (11 ⁄ 19; 57.9%) during the infection.
In contrast, there was no gender predomin-
ance among patients with PDRPA colonisation
(male:female ratio = 9 : 9), and fever was also less
frequent in this group (4 ⁄ 18; 22.2%).
Most of the patients with PDRPA infection had
yielded a previous culture of P. aeruginosa (18 ⁄ 19;
94.7%); only one patient yielded PDRPA as the
ﬁrst P. aeruginosa isolate. The time from ﬁrst
isolation of P. aeruginosa to the culture of PDRPA
was c. 173 days. Patients with PDRPA infection
had a higher mortality rate (14 ⁄ 19; 73.7%), and
those who died had an average survival duration
of 19 days following a positive PDRPA culture.
Most of the fatal cases had received multiple
long-course treatments with anti-pseudomonal
Table 1. Demographic and clinical characteristics of 37 patients infected or colonised with pandrug-resistant Pseudomonas
aeruginosa (PDRPA) treated at National Taiwan University Hospital in 2003
Characteristic (no. of patients) Infection (n = 19) Colonisation (n = 18) Total (n = 37)
Sex (n = 37)
Male ⁄ female, n (%) 15 (78.9) ⁄ 4 (21.1) 9 (50.0) ⁄ 9 (50.0) 24 (64.9) ⁄ 13 (35.1)
Age, mean ⁄ range (years) 62.8 ⁄ 39–90 63.6 ⁄ 19–83 63.2 ⁄ 19–90
Setting
ICU ⁄ non-ICU, n (%) 18 (94.7) ⁄ 1 (5.3) 16 (99.9) ⁄ 2 (11.1) 34 (91.9) ⁄ 3 (8.1)
SICU ⁄MICU ⁄ SICU ⁄MICU, n (%) 9 (47.4) ⁄ 5 (26.3) ⁄ 3 (15.8) 8 (44.4) ⁄ 7 (38.9) ⁄ 1 (5.6) 18 (48.6) ⁄ 13 (35.1) ⁄ 3 (8.1)
Underlying disease
Immunosuppression, n (%) 12 (63.2) 8 (44.4) 20 (54.1)
Malignancy, n (%) 6 (31.6) 4 (22.2) 10 (27.0)
Cardiac disease, n (%) 6 (31.6) 7 (38.9) 13 (35.1)
Renal disease, n (%) 10 (52.6) 7 (38.9) 17 (45.9)
Diabetes mellitus, n (%) 5 (26.3) 7 (38.9) 12 (32.4)
Mechanical ventilation, n (%) 14 (73.3) 10 (55.6) 24 (64.9)
Type of infection
Pneumonia, n (%) 17 (45.9) 17 (45.9)
Catheter-related bacteraemia, n (%) 1 (2.7) 1 (2.7)
Anal infection, n (%) 1 (2.7) 1 (2.7)
Colonisation 18 (48.6) 18 (48.6)
PDRPA as the ﬁrst P. aeruginosa isolate, n (%) 1 (5.3) 8 (44.4) 9 (24.3)
Previous P. aeruginosa isolate, n (%) 18 (94.7) 10 (55.6) 28 (75.7)
Days between non-PDR P. aeruginosa and PDRPA
isolation, mean ⁄ range (days)
173.2 ⁄ 24–914 47.4 ⁄ 14–91 128.3 ⁄ 14–914
Hospitalisation data
Initial ICU admission, n (%) 5 (26.3) 7 (38.9) 12 (32.4)
Initial general ward admission, n (%) 14 (73.7) 11 (61.1) 25 (67.6)
Total days of hospitalisation, mean ⁄ range (days) 87.4 ⁄ 33–1045 45.1 ⁄ 11–218 132.5 ⁄ 11–1045
Total days of ICU hospitalisation, mean ⁄ range (days) 19.4 ⁄ 8–554 18.1 ⁄ 5–135 58.1 ⁄ 5–554
Days of hospitalisation before PDRPA culture positive,
mean ⁄ range (days)
67.1 ⁄ 3–927 20.2 ⁄ 1–135 87.3 ⁄ 1–927
Days of hospitalisation after PDRPA culture positive,
mean ⁄ range (days)
19.8 ⁄ 1–117 24.4 ⁄ 4 ⁄ 193 44.2 ⁄ 1–193
Clinical manifestations
Leukocytosis, n (%) 15 (78.9) 11 (61.1) 26 (70.2)
Fever, n (%) 11 (57.9) 4 (22.2) 15 (40.5)
Shock, n (%) 3 (15.8) 1 (5.6) 4 (10.8)
DIC, n (%) 2 (10.5) 0 (0.0) 2 (5.4)
Mean MODS on the day of PDRPA culture ⁄ range 5 ⁄ 0–15 2 ⁄ 0–7 4 ⁄ 0–15
Hospital mortality, n (%) 14 (73.7) 2 (11.1) 16 (43.2)
Invasive procedures before PDRPA
Urinary catheter, n (%) 18 (94.7) 18 (100.0) 36 (97.3)
Central venous catheter, n (%) 18 (94.7) 17 (94.4) 35 (94.6)
Arterial catheter, n (%) 16 (84.2) 17 (94.4) 33 (89.2)
Pulmonary artery catheter, n (%) 2 (10.5) 2 (11.1) 4 (10.8)
Chest tube, n (%) 2 (10.5) 2 (11) 4 (10.8)
ICU, intensive care unit; SICU, surgical intensive care unit; MICU, medical intensive care unit; DIC, disseminated intravascular coagulation; MODS, multiple organ
dysfunction score.
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antibiotics before the isolation of PDRPA. These
ﬁndings suggest that PDRPA infections are
mostly endogenous, with relatively few exogen-
ous cases. Previous treatment with anti-pseudo-
monal antibiotics can suppress P. aeruginosa
infection, but fail to eradicate the pathogen
completely. As P. aeruginosa develops resistance
to antibiotics after a long period of treatment, a
lack of response suggests the need for a change to
antibiotics to which the organism is still sensitive.
In a prospective observational study, Rello et al.
[22] reported that most recurrent episodes of
P. aeruginosa pneumonia in ventilated patients are
associated with the persistence of a strain present
in a previous infection. In the present study, nine
of 18 colonised patients yielded PDRPA as the
ﬁrst isolate of a P. aeruginosa strain. Patients who
were only colonised initially with PDRPA had a
far lower mortality rate (2 ⁄ 18; 11.1%), and both of
the fatal cases died because of underlying disease,
not PDRPA. There appears to be an association
Table 3. Univariate analysis of factors inﬂuencing mortal-
ity among 37 patients infected or colonised with pandrug-
resistant Pseudomonas aeruginosa
Variable
Death ⁄ total
(%)
OR of death
(95% CI) p
Age >60 years 10 ⁄ 23 (43.5) 1.026 (0.268–3.923) 1.00
£60 years 6 ⁄ 14 (42.9) 1
Gender Male 13 ⁄ 23 (56.5) 4.767 (1.043–21.787) 0.048
Female 3 ⁄ 14 (21.4) 1
Diabetes mellitus Yes 5 ⁄ 12 (41.7) 0.909 (0.226–3.661) 1.00
No 11 ⁄ 25 (44) 1
Cancer Yes 5 ⁄ 10 (50) 1.455 (0.338–6.251) 0.716
No 11 ⁄ 27 (40.7) 1
Heart disease Yes 4 ⁄ 13 (30.8) 0.444 (0.107–1.846) 0.315
No 12 ⁄ 24 (50) 1
Haemodialysis Yes 8 ⁄ 12 (66.7) 4.250 (0.982–18.395) 0.077
No 8 ⁄ 23 (32) 1
Renal disease Yes 10 ⁄ 17 (58.8) 3.333 (0.856–12.978) 0.104
No 6 ⁄ 20 (30) 1
Infection Yes 14 ⁄ 19 (73.7) 22.400 (3.741–134.141) < 0.001
No 2 ⁄ 18 (11.1) 1
Fever Yes 10 ⁄ 15 (66.7) 5.333 (1.282–22.192) 0.023
No 6 ⁄ 22 (27.3) 1
Leukocytosis Yes 13 ⁄ 26 (50) 2.667 (0.575–12.358) 0.285
No 3 ⁄ 11 (27.3) 1
Shock Yes 3 ⁄ 4 (75) 4.615 (0.432–49.296) 0.296
No 13 ⁄ 33 (39.4) 1
DIC Yes 2 ⁄ 2 (100) 0.400 (0.267–0.600) 0.180
No 14 ⁄ 35 (40) 1
MODS >6 4 ⁄ 7 (57.112) 2.000 (0.378–10.578) 0.437
£6 12 ⁄ 30 (40) 1
Mechanical ventilation Yes 11 ⁄ 24 (45.8) 1.354 (0.342–5.360) 0.739
No 5 ⁄ 13 (38.5) 1
DIC, disseminated intravascular coagulation; MODS, multiple organ dysfunction
score.
Table 2. Receipt of antimicrobial agents before notiﬁcation
of a positive culture of pandrug-resistant Pseudomonas
aeruginosa
Antimicrobial agent (s) received
No. (%) of
patients
Duration of antibiotic
usage, mean ⁄ range (days)
Anti-pseudomonal penicillins
Piperacillin-tazobactam 12 (32.4) 10.9 ⁄ 1–27
Ticarcillin-clavulanate 9 (24.3) 9 ⁄ 2–21
Third-generation cephalosporins
Ceftazidime 15 (40.5) 23.3 ⁄ 3–90
Flomoxef 7 (18.9) 8.4 ⁄ 2–19
Ceftriaxone 3 (8.1) 4 ⁄ 1–8
Cefotaxime 1 (2.7) 3
Fourth-generation cephalosporins
Cefepime 15 (40.5) 24.3 ⁄ 2–179
Cefpirome 2 (5.4) 6.5 ⁄ 4–9
Carbapenems
Imipenem 18 (48.6) 29.1 ⁄ 1–146
Meropenem 14 (37.8) 23.2 ⁄ 1–81
Monobactam
Aztreonam 4 (10.8) 24.5 ⁄ 3–43
Aminoglycosides
Amikacin 13 (35.1) 25.6 ⁄ 3–147
Gentamicin 10 (27.0) 7.8 ⁄ 2–20
Tobramycin 1 (2.7) 20
Fluoroquinolones
Ciproﬂoxacin 20 (54.1) 34.4 ⁄ 2–355
Levoﬂoxacin 4 (10.8) 6.3 ⁄ 1–10
Metronidazole 11 (29.7) 12.1 ⁄ 4–42
Patients with PDRPA colonisation
Su
rv
iv
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 p
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y
Patients with PDRPA
infection
Hospitalisation days
Fig. 1. Survival probability for patients with pandrug-
resistant Pseudomonas aeruginosa (PDRPA) infection and
patients with PDRPA colonisation
Table 4. Multivariate analysis (backward method) of fac-
tors inﬂuencing mortality among 37 patients with pan-
drug-resistant Pseudomaonas aeruginosa
Variables in the equation p OR of death (95% CI)
Step 1 Gender 0.384 2.269 (0.359–14.346)
Haemodialysis 0.316 1.753 (0.586–5.245)
Infection 0.228 2.891 (0.515–16.241)
Fever 0.101 2.901 (0.811–10.370)
Step 2 Haemodialysis 0.330 1.717 (0.578–5.096)
Infection 0.081 4.049 (0.841–19.501)
Fever 0.029 3.774 (1.148–12.406)
Step 3 Infection 0.093 3.799 (0.800–18.036)
Fever 0.016 4.218 (1.305–13.635)
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between acquisition of PDRPA and long-term
usage of anti-pseudomonal agents and a history
of ICU admission. Persistence of a multidrug-
resistant P. aeruginosa clone in the burns ICU of
NTUH hospital has been reported previously [17],
which may explain the higher risk of colonisation
and infection in this patient group.
The use of anti-pseudomonal antibiotics, par-
ticularly ciproﬂoxacin, has been reported previ-
ously to be a risk-factor for the emergence of
MDRPA in the ICU [23]. Data supportive of this
association were also found in the present study.
The antibiotics used most widely before positive
culture of PDRPA were ciproﬂoxacin (20 patients;
54.1%), imipenem (18 patients; 48.6%) and me-
ropenem (14 patients; 37.8%). It can be speculated
that there is a relationship between the emergence
of PDRPA and the use of ciproﬂoxacin and
carbapenems [24], but further investigation of
the resistance mechanisms in these isolates is
required.
Previous studies of risk-factors for multidrug-
resistant P. aeruginosa nosocomial infection have
found that age, a high severity index, a bed-
ridden condition, transfer from other units, naso-
gastric feeding, urinary catheterisation, and
exposure to b-lactams (OR 2.5) or ﬂuoroquinolo-
nes (OR 4.1) in the preceding 7 days were linked
to nosocomial MDRPA infection among hospital-
ised patients [25,26]. Exposure to ﬂuoroquinolo-
nes (OR 4.7) or surgical procedures (OR 0.5) were
linked to the isolation of MDRPA among patients
infected by P. aeruginosa. Cao et al. [27] found that
mechanical ventilation and previous use of
imipenem or meropenem were independent
risk-factors for MDRPA infection. These data
suggest there may be a relationship between
prolonged use of b-lactams, ﬂuoroquinolones
and carbapenems, and the development of pan-
drug resistance in P. aeruginosa.
In the present study, pandrug resistance was
deﬁned as resistance to all commercially avail-
able antibiotics tested (i.e., ceftazidime, cefepime,
ticarcillin ⁄ clavulanate, piperacillin ⁄ tazobactam,
aztreonam, imipenem, meropenem, gentamicin,
amikacin, levoﬂoxacin and ciproﬂoxacin). Colistin
has anti-pseudomonal activity and has been used
previously, either intravenously or in an aerosol
form, for treatment of pneumonia caused by
MDRPA [28,29]. Colistin was not available in
Taiwanese hospitals at the time of this study, and
is mostly used in Taiwan in veterinary practice,
and in livestock and poultry farming. The PDRPA
isolates tested in this study were all susceptible to
colistin, indicating that this agent may be an
alternative for the treatment of PDRPA infections.
In conclusion, this study documented the
emergence of PDRPA acquisition among hospi-
talised patients. Survival of infected patients was
determined largely by the underlying condition of
the patient. Most infected patients had yielded a
previous P. aeruginosa culture and had been trea-
ted with long courses of multiple anti-pseudomo-
nal antibiotics. No speciﬁc antibiotics were found
to be effective against PDRAB sepsis. Therefore,
use of proper and adequate antibiotics (but not
open-ended or longer treatment) for initial
P. aeruginosa infections offers the best solution to
prevent the emergence of PDRPA and the asso-
ciated morbidity and mortality.
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